$34.71
1.88% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Stock price

$34.71
+0.21 0.61% 1M
+4.76 15.89% 6M
+2.41 7.46% YTD
+5.92 20.56% 1Y
-3.68 9.59% 3Y
-2.30 6.21% 5Y
-2.30 6.21% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.64 1.88%
ISIN
US4131971040
Symbol
HRMY
Sector
Industry

Key metrics

Market capitalization $1.98b
Enterprise Value $1.79b
P/E (TTM) P/E ratio 16.43
EV/FCF (TTM) EV/FCF 8.15
EV/Sales (TTM) EV/Sales 2.63
P/S ratio (TTM) P/S ratio 2.90
P/B ratio (TTM) P/B ratio 3.32
Revenue growth (TTM) Revenue growth 25.83%
Revenue (TTM) Revenue $681.88m
EBIT (operating result TTM) EBIT $175.30m
Free Cash Flow (TTM) Free Cash Flow $220.18m
Cash position $410.48m
EPS (TTM) EPS $2.11
P/E forward 14.97
P/S forward 2.78
EV/Sales forward 2.52
Short interest 46.85%
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Harmony Biosciences Holdings forecast:

7x Buy
78%
2x Sell
22%

Analyst Opinions

9 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
78%
Sell
22%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
682 682
26% 26%
100%
- Direct Costs 169 169
32% 32%
25%
512 512
24% 24%
75%
- Selling and Administrative Expenses 171 171
28% 28%
25%
- Research and Development Expense 141 141
153% 153%
21%
200 200
11% 11%
29%
- Depreciation and Amortization 24 24
0% 0%
4%
EBIT (Operating Income) EBIT 175 175
12% 12%
26%
Net Profit 123 123
19% 19%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
Investors Business Daily
4 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
PRNewsWire
5 days ago
PLYMOUTH MEETING, Pa. , Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Citi's 2024 Global Healthcare Conference Location: Miami Tuesday, December 3, 2024 Piper Sandler 36th Annual Healthcare Conference Location: New York City Fireside Chat: Wednesday,...
Positive
Seeking Alpha
15 days ago
Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 reached $186 million. The company surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting rapid growth.
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 246
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today